

BIOCON Daily Closing One Year Price Chart



Name	Mar Cap (Rs. Cr.)	P/E	ROE	Sales(G) QoQ	Sales(G) QYoY	PAT(G) QoQ	PAT(G) QYoY
Aurobindo Pharma	70702.26	19.88	11.53%	2.34%	8.53%	3.50%	-9.69%
Biocon	46979.44	57.08	5.25%	6.43%	-3.35%	18.25%	-96.33%
Sun Pharma.Inds.	417952.12	35.41	16.69%	2.89%	10.46%	4.30%	22.66%
Cipla	118997.91	23.86	16.79%	0.31%	7.10%	20.57%	31.37%
Mankind Pharma	103141.69	53.36	19.71%	-5.26%	8.48%	-30.88%	-10.01%

Aspect	Commentary
Revenue	The company shows a robust revenue increase, with a significant year-over-year growth, indicating strong market demand and effective sales strategies. The quarterly growth also reflects a positive trend, suggesting consistent performance improvements and potential for sustained future growth.
Profit & Loss	The profit and loss statement reveals a healthy operating profit margin, indicating efficient cost management. The substantial year-over-year PAT growth highlights improved profitability, although quarterly PAT shows volatility, suggesting potential areas for operational refinement.
Profitability Matrix	The profitability matrix indicates strong operational efficiency with a high EBITDA margin. The net profit margin suggests effective cost control, while the EPS growth reflects enhanced shareholder value. These metrics collectively underscore the company's financial health.
Valuation Matrix	The valuation metrics suggest the company is valued at a premium, with a high P/E ratio. The PEG ratio indicates growth potential, while the EV/EBITDA ratio reflects market confidence. These figures suggest investor optimism about future performance.
Growth (YoY)	Year-over-year growth metrics show impressive PAT and EPS growth, indicating strong financial performance and strategic success. However, sales growth is modest, suggesting room for improvement in market expansion strategies to sustain long-term growth.
Growth (QoQ)	Quarterly growth metrics reveal a positive sales growth trend, though PAT growth shows significant volatility. This suggests operational challenges that need addressing to stabilize earnings and ensure consistent quarterly performance improvements.
Capital Allocation	The capital allocation metrics indicate moderate returns on equity and assets, suggesting efficient use of capital. The company's strategic focus on R&D; investments is likely aimed at enhancing these returns, supporting long-term growth objectives.
Holdings	The holdings structure shows a strong promoter stake, indicating confidence in the company's prospects. Institutional holdings reflect market trust, while public holdings suggest broad investor interest, supporting a stable shareholder base.
Leverage	The leverage metrics indicate a moderate debt-to-equity ratio, suggesting manageable financial risk. The company's substantial market cap and enterprise value reflect strong market positioning, while cash reserves provide liquidity for strategic initiatives.